(2S)-2-[3-[[3-(4-chlorobenzoyl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid | 668456-95-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (2S)-2-[3-[[3-(4-chlorobenzoyl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid
• 英文别名: (S)-2-(3-((3-(4-chlorobenzoyl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl)methyl)phenoxy)propanoic acid；(2S)-2-[3-[[3-(4-chlorobenzoyl)-2-methyl-6-(trifluoromethoxy)indol-1-yl]methyl]phenoxy]propanoic acid
• CAS: 668456-95-9
• 化学式: C₂₇H₂₁ClF₃NO₅
• 分子量: 531.916
• InChiKey: DHUATBAZHILHIC-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  37
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  77.8
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  C₃₁H₂₉ClF₃NO₅ 在 水 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 (2S)-2-[3-[[3-(4-chlorobenzoyl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid
  参考文献：
  名称：

  Discovery of a Peroxisome Proliferator Activated Receptor γ (PPARγ) Modulator with Balanced PPARα Activity for the Treatment of Type 2 Diabetes and Dyslipidemia

  摘要：

  A series of 3-acylindole-1-benzylcarboxylic acids were designed and synthesized while searching for a PPAR gamma modulator with additional moderate intrinsic PPAR alpha agonistic activity. 2-[3-[[3-(4-Chlorobenzoyl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-(2R)-butanoic acid (12d) was identified as such an agent which demonstrated potent efficacy in lowering both glucose and lipids in multiple animal models with significantly attenuated side effects such as fluid retention and heart weight gain associated with PPAR gamma full agonists, The moderate PPAR alpha activity of 12d not only contributed to the agent's ability to manage lipid profiles but also appears to have potentiated its PPAR gamma efficacy in lowering glucose levels in preclinical diabetic animal models.

  DOI：

  10.1021/jm900367w

文献信息

• Indoles having anti-diabetic activity
  申请人：Acton III J. John

  公开号：US20050277685A1

  公开（公告）日：2005-12-15

  Indoles having aryloxyalkanoic acid substituents or arylalkanoic acid substituents are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.

  具有芳氧基烷酸取代基或芳基烷酸取代基的吲哚类化合物是PPARγ激动剂或部分激动剂，可用于治疗和控制II型糖尿病的症状性高血糖，以及常与II型糖尿病相关的失调脂质代谢、高脂血症、高胆固醇血症、高甘油三酯血症和肥胖症。
• INDOLES HAVING ANTI-DIABETIC ACTIVITY
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP1537078B1

  公开（公告）日：2010-04-14
• US7186746B2
  申请人：——

  公开号：US7186746B2

  公开（公告）日：2007-03-06
• US7345085B2
  申请人：——

  公开号：US7345085B2

  公开（公告）日：2008-03-18
• Discovery of a Peroxisome Proliferator Activated Receptor γ (PPARγ) Modulator with Balanced PPARα Activity for the Treatment of Type 2 Diabetes and Dyslipidemia
  作者：Weiguo Liu、Kun Liu、Harold B. Wood、Margaret E. McCann、Thomas W. Doebber、Ching H. Chang、Taro E. Akiyama、Monica Einstein、Joel P. Berger、Peter T. Meinke

  DOI：10.1021/jm900367w

  日期：2009.7.23

  A series of 3-acylindole-1-benzylcarboxylic acids were designed and synthesized while searching for a PPAR gamma modulator with additional moderate intrinsic PPAR alpha agonistic activity. 2-[3-[[3-(4-Chlorobenzoyl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-(2R)-butanoic acid (12d) was identified as such an agent which demonstrated potent efficacy in lowering both glucose and lipids in multiple animal models with significantly attenuated side effects such as fluid retention and heart weight gain associated with PPAR gamma full agonists, The moderate PPAR alpha activity of 12d not only contributed to the agent's ability to manage lipid profiles but also appears to have potentiated its PPAR gamma efficacy in lowering glucose levels in preclinical diabetic animal models.